Markets:

Overview

News

Currencies

International

Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

4.450 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Dow Jumps 150 Points; Icosavax Shares Plunge ↗

June 29, 2022

U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday.

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics ↗

May 23, 2022

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Where Atara Biotherapeutics Stands With Analysts ↗

May 24, 2022

Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here's What You Need To Know ↗

May 23, 2022

HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00. Shares of Atara Biotherapeutics are trading down 3.1%...

Via Benzinga

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗

May 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 20, 2022

Via Benzinga

Fujifilm To Buy Cell Therapy Plant From Atara For $100M ↗

January 27, 2022

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA)

Via Benzinga

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗

May 20, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 19, 2022

Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022 ↗

May 10, 2022

Upgrades

Via Benzinga

Atara Biotherapeutics Earnings Preview ↗

May 04, 2022

Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Atara...

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 01, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 172.1% to $0.92 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 157.8...

Via Benzinga

44 Stocks Moving In Tuesday's Mid-Day Session ↗

March 01, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 02, 2022

Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...

Via Benzinga

80 Biggest Movers From Yesterday ↗

March 02, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...

Via Benzinga

Preview: Atara Biotherapeutics's Earnings ↗

February 25, 2022

Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 01, 2022

During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the...

Via Benzinga

Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial ↗

February 18, 2022

Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara...

Via Benzinga

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study ↗

January 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 14, 2021

Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $...

Via Benzinga

The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks ↗

December 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that...

Via Benzinga

Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients ↗

December 14, 2021

Atara Biotherapeutics Inc (NASDAQ: ATRA) posted efficacy and safety results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

December 14, 2021

Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

20 Stocks Moving in Tuesday's Pre-Market Session ↗

December 14, 2021

Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement...

Via Benzinga

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗

December 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...

Via Benzinga

How Bad Are Atara Biotherapeutics's Earnings? | Return On Capital Employed ↗

November 05, 2021

Atara Biotherapeutics (NASDAQ:ATRA) brought in sales totaling $5.37 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 0.96%, resulting in a...

Via Benzinga

Atara Biotherapeutics, inc (ATRA) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

ATRA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

Headline News about Atara Biotherapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today